RN1701 injection for relapsed B-cell lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an investigational drug called RN1701 for people with certain types of B-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell lymphoma, like large B-cell, follicular, mantle-cell, or transformed lymphoma, that is CD19 or CD20 positive.
- Your cancer must have come back or not responded well to at least one or two prior treatments.
- You need to have at least one tumor that can be measured on a scan (≥1.5 cm for lymph nodes, ≥1.0 cm elsewhere).
- You should be between 18 and 75 years old and in fairly good health (able to care for yourself).
- Blood test results must meet minimum levels for red cells, platelets, white cells, liver and kidney function.
- You cannot have had certain recent cancer treatments or other serious medical conditions as listed in the full criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new injection called RN1701 for B-cell lymphomas (blood cancers) that have not responded to or have returned after prior treatments. The study aims to see if this therapy can help patients whose cancer is difficult to treat.
This phase 1 trial tests an investigational treatment called RN1701 for people with certain types of B-cell lymphoma that have come back or not responded to previous therapies. The goal is to see if the drug is safe and effective.
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
This trial tests a new immunotherapy, RN1201, for people with certain blood cancers (like multiple myeloma, leukemia, or lymphoma) that have come back or not responded to standard treatments. It aims to see if this treatment can help when other options have stopped working.
This early-phase trial tests a new cell therapy called RS001 for people with certain B-cell blood cancers (lymphoma or leukemia) that haven't responded to other treatments. It aims to see if this personalized therapy can help when standard options have stopped working.
Hear when a new Relapsed/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.